RelieVRx headset
DeviceRelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
NCT Number: NCT04010266
This is a single-center, prospective, randomized, controlled study of the appliedVR RelieVRx headset in subjects undergoing Total Knee Arthroplasty (TKA). This study will evaluate two primary endpoints - effectiveness of a single use of RelieVRx in the reduction of acute postoperative pain by 20%; and overall effectiveness of RelieVRx as an opioid-sparing intervention, where opioid consumption is reduced by at least 20% over a 90-day postoperative period in the interventional, standard of care (SOC) plus RelieVRx group compared to the control, SOC group.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Geisinger Medical Center, Danville, Pennsylvania, United States
This is a single-center, prospective, randomized, controlled study of the appliedVR RelieVRx headset in subjects undergoing Total Knee Arthroplasty (TKA). Patients will be randomized to one of the two groups after study enrollment, and patients in the test arm will be educated about the device preoperatively to facilitate its use in the acute post-operative period. The goals of VR will be presented in the context of an alternate method of pain control to opioids. This study will evaluate two primary endpoints - effectiveness of a single use of RelieVRx in the reduction of acute postoperative pain by 20%; and overall effectiveness of RelieVRx as an opioid-sparing intervention, where opioid consumption is reduced by at least 20% over a 90-day postoperative period in the interventional, standard of care (SOC) plus RelieVRx group compared to the control, SOC group.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
Time frame: 90 days
Visual Analog Pain scale; worst 0-10 best
Time frame: 90 days
Morphine Milligram Equivalents (MME)
Time frame: 90 days
short form of knee injury and osteoarthritis outcome score; worst 0 - 100 best
Time frame: 90 days
This is a measure of quality of life. The VR-12 provides a physical component score (i.e., physical health domain) that provides larger weights for four of the domains (physical function, role-physical, bodily pain, and general health). This is a 12 items survey. VR-12 scores are standardized using a T-score metric with a mean of 50 and a standard deviation of 10. Larger values imply greater physical function and quality of life.
AppliedVR Inc.
Industry
Safety and Effectiveness of Virtual Reality Utilizing RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04749628
Arthritis, Joint Diseases
New York, United States
View Trial DetailsNCT07164664
Acute Pain, Neurologic Manifestations
Samsun, Turkey (Türkiye)
View Trial DetailsNCT07253610
Body Weight, Laparoscopic Sleeve Gastrectomy (LSG)
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03726268
Neurologic Manifestations, Opioid Use
Durham, North Carolina, United States
View Trial Details